These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12606940)

  • 1. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
    Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W; Lebowitz PF; Prendergast GC
    Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W; Prendergast GC
    Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
    Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
    Liu A; Prendergast GC
    FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
    Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
    J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
    van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
    Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
    Lebowitz PF; Davide JP; Prendergast GC
    Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade.
    Oldham SM; Cox AD; Reynolds ER; Sizemore NS; Coffey RJ; Der CJ
    Oncogene; 1998 May; 16(20):2565-73. PubMed ID: 9632133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
    Ader I; Toulas C; Dalenc F; Delmas C; Bonnet J; Cohen-Jonathan E; Favre G
    Oncogene; 2002 Sep; 21(39):5998-6006. PubMed ID: 12203112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin' up: RhoB in cancer and apoptosis.
    Prendergast GC
    Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
    Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.